Stavroula Tekkela
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Stavroula Tekkela has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Alexandros Onoufriadis
Laboratory of Medical Biology and Genetics, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
2 shared publications - Georgios Theocharidis
Joslin-Beth Israel Deaconess Foot Center and The Rongxiang Xu, MD, Center for Regenerative Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
2 shared publications - John Alexander McGrath
Department of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University , Tainan
2 shared publications - Aristidis Veves
Joslin-Beth Israel Deaconess Foot Center and The Rongxiang Xu, MD, Center for Regenerative Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
1 shared publication - Emanuel Rognoni
Centre for Cell Biology and Cutaneous Research, Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London , London
1 shared publication
Latest Publications
- 20 July 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 195 (5) , 722-723
The amphiregulin–epidermal growth factor receptor axis: a new driver and therapeutic target in keloids
- 20 July 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 195 (5) , 722-723
The amphiregulin–epidermal growth factor receptor axis: a new driver and therapeutic target in keloids
- Open Access
- 7 May 2023
- Published by Wiley in Experimental Dermatology
- Vol. 32 (6) , 731-739
Spatial transcriptomics in human skin research
Spatial transcriptomics is a revolutionary technique that enables researchers to characterise tissue architecture and localisation of gene expression. A plethora of technologies that map gene expression are currently being developed, aiming to facilitate spatially resolved, high‐dimensional assessment of gene transcription in the context of human skin research. Knowing which gene is expressed by which cell and in which location within skin, facilitates understanding of skin function and dysfunction in both health and disease. In this review, we summarise the available spatial transcriptomic methods and we describe their application to a broad spectrum of dermatological diseases.
- 7 May 2023
- Published by Wiley in Experimental Dermatology
- Vol. 32 (6) , 731-739
Open AccessSpatial transcriptomics in human skin research
Spatial transcriptomics is a revolutionary technique that enables researchers to characterise tissue architecture and localisation of gene expression. A plethora of technologies that map gene expression are currently being developed, aiming to facilitate spatially resolved, high‐dimensional assessment of gene transcription in the context of human skin research. Knowing which gene is expressed by which cell and in which location within skin, facilitates understanding of skin function and dysfunction in both health and disease. In this review, we summarise the available spatial transcriptomic methods and we describe their application to a broad spectrum of dermatological diseases.
- Open Access
- 4 March 2022
- Published by Wiley in Experimental Dermatology
- Vol. 31 (5) , 655-673
Single‐cell transcriptomics in human skin research: available technologies, technical considerations and disease applications
Single‐cell technologies have revolutionized research in the last decade, including for skin biology. Single‐cell RNA sequencing has emerged as a powerful tool allowing the dissection of human disease pathophysiology at unprecedented resolution by assessing cell‐to‐cell variation, facilitating identification of rare cell populations and elucidating cellular heterogeneity. In dermatology, this technology has been widely applied to inflammatory skin disorders, fibrotic skin diseases, wound healing complications and cutaneous neoplasms. Here, we discuss the available technologies and technical considerations of single‐cell RNA sequencing and describe its applications to a broad spectrum of dermatological diseases.
- 4 March 2022
- Published by Wiley in Experimental Dermatology
- Vol. 31 (5) , 655-673
Open AccessSingle‐cell transcriptomics in human skin research: available technologies, technical considerations and disease applications
Single‐cell technologies have revolutionized research in the last decade, including for skin biology. Single‐cell RNA sequencing has emerged as a powerful tool allowing the dissection of human disease pathophysiology at unprecedented resolution by assessing cell‐to‐cell variation, facilitating identification of rare cell populations and elucidating cellular heterogeneity. In dermatology, this technology has been widely applied to inflammatory skin disorders, fibrotic skin diseases, wound healing complications and cutaneous neoplasms. Here, we discuss the available technologies and technical considerations of single‐cell RNA sequencing and describe its applications to a broad spectrum of dermatological diseases.
- Open Access
- 17 September 2021
- Published by Morressier GmbH
ESDR165 - Allelic specific COL7A1 correction in dominant dystrophic epidermolysis bullosa fibroblasts
Dominant dystrophic epidermolysis bullosa (DDEB) is an inherited blistering skin disease resulting from heterozygous mutations in COL7A1, encoding the anchoring fibril protein, type VII collagen (C7). The prototypic mutation is a single nucleotide substitution affecting a glycine residue within the C7 triple helix, resulting in dominant-negative interference between the mutant and
- 17 September 2021
- Published by Morressier GmbH
Open AccessESDR165 - Allelic specific COL7A1 correction in dominant dystrophic epidermolysis bullosa fibroblasts
Dominant dystrophic epidermolysis bullosa (DDEB) is an inherited blistering skin disease resulting from heterozygous mutations in COL7A1, encoding the anchoring fibril protein, type VII collagen (C7). The prototypic mutation is a single nucleotide substitution affecting a glycine residue within the C7 triple helix, resulting in dominant-negative interference between the mutant and